» Articles » PMID: 39013872

Systems Modeling of Oncogenic G-protein and GPCR Signaling Reveals Unexpected Differences in Downstream Pathway Activation

Overview
Specialty Biology
Date 2024 Jul 16
PMID 39013872
Authors
Affiliations
Soon will be listed here.
Abstract

Mathematical models of biochemical reaction networks are an important and emerging tool for the study of cell signaling networks involved in disease processes. One promising potential application of such mathematical models is the study of how disease-causing mutations promote the signaling phenotype that contributes to the disease. It is commonly assumed that one must have a thorough characterization of the network readily available for mathematical modeling to be useful, but we hypothesized that mathematical modeling could be useful when there is incomplete knowledge and that it could be a tool for discovery that opens new areas for further exploration. In the present study, we first develop a mechanistic mathematical model of a G-protein coupled receptor signaling network that is mutated in almost all cases of uveal melanoma and use model-driven explorations to uncover and explore multiple new areas for investigating this disease. Modeling the two major, mutually-exclusive, oncogenic mutations (Gα and CysLTR) revealed the potential for previously unknown qualitative differences between seemingly interchangeable disease-promoting mutations, and our experiments confirmed oncogenic CysLTR was impaired at activating the FAK/YAP/TAZ pathway relative to Gα. This led us to hypothesize that CYSLTR2 mutations in UM must co-occur with other mutations to activate FAK/YAP/TAZ signaling, and our bioinformatic analysis uncovers a role for co-occurring mutations involving the plexin/semaphorin pathway, which has been shown capable of activating this pathway. Overall, this work highlights the power of mechanism-based computational systems biology as a discovery tool that can leverage available information to open new research areas.

Citing Articles

Going Rogue: Mechanisms, Regulation, and Roles of Mutationally Activated G in Human Cancer.

Dwyer M, Aumiller J, Wedegaertner P Mol Pharmacol. 2024; 106(5):198-215.

PMID: 39187387 PMC: 11493338. DOI: 10.1124/molpharm.124.000743.

References
1.
Kraikivski P, Chen K, Laomettachit T, Murali T, Tyson J . From START to FINISH: computational analysis of cell cycle control in budding yeast. NPJ Syst Biol Appl. 2017; 1:15016. PMC: 5516803. DOI: 10.1038/npjsba.2015.16. View

2.
Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

3.
Wong O, Nitkunan T, Oinuma I, Zhou C, Blanc V, Brown R . Plexin-B1 mutations in prostate cancer. Proc Natl Acad Sci U S A. 2007; 104(48):19040-5. PMC: 2141904. DOI: 10.1073/pnas.0702544104. View

4.
Bender R, Mac Gabhann F . Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. BMC Syst Biol. 2015; 9:55. PMC: 4559909. DOI: 10.1186/s12918-015-0201-z. View

5.
Field M, Decatur C, Kurtenbach S, Gezgin G, van der Velden P, Jager M . PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res. 2016; 22(5):1234-42. PMC: 4780366. DOI: 10.1158/1078-0432.CCR-15-2071. View